Manel Esteller, Josep Baselga i Joan Massagué reben el XXVIII Premi Internacional Catalunya de mans del President Puigdemont

El Parlamento entrega la medalla de honor al Dr. Manel Esteller

Manel Esteller recibe el Premio Nacional de Investigación 2015


PNAS, Proceedings of the National Academy of Sciences - Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer >>


Cancer Research - RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation >>


The Lancet Oncology - Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis >>


Nature Medicine - Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGF >>


Genome Biology - Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer >>


Oncogene - . Gene Amplification-Associated Overexpression of the RNA Editing Enzyme ADAR1 Enhances Human Lung T >>


Neuropsychopharmacology - Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a >>



The Bellvitge Institute for Biomedical Research (IDIBELL) is a research foundation set up on 16th June 2004 as a separate legal entity resulting from a change in name of the former August Pi i Sunyer (FAPS) Foundation, set up in 1988. IDIBELL has scientific cooperation agreements with the following institutions/centres:

- University of Barcelona (UB) and its science park
- Bellvitge University Hospital (HUB)

- Catalan Institute of Oncology (ICO)

- Institute for Imaging Diagnosis (IDI)

- Transfusion Centre and Tissue Bank (CTBT)

manel esteller

It is a great pleasure to announce the launching in 2008 of a new research program within the IDIBELL devoted to basic research, the "Cancer Epigenetics and Biology Program" (PEBC) that I have the honour to direct. The research program is supported by the Department of Health de la Generalitat de Catalunya, Ministerio de Sanidad y Consumo, Ministerio de Educación y Ciencia and the Catalan Institution for Research and Advanced Studies (ICREA).

Current research projects developed at the PEBC include, but are not restricted to, cancer epigenetics, chromatin and stem cell biology, aging, cell cycle and transformation, imprinting and the identification of cancer genes.

We encourage unsolicited applications at all times from highly motivated candidates with excellent qualifications in biomedical and life sciences, molecular and cellular biology or biochemistry for different positions (Junior Group Leaders, Research Associates, Postdoctoral Fellows, PhD Students, Technicians, Scientific Management and Administration).

The PEBC is located in the outskirts of Barcelona (Catalonia, Spain) within walking distance of metro station and ten minutes driving from the airport. It is located in a biomedical and scientific campus that include two Hospitals (Hospital de Bellvitge and Hospital Duran I Reynals), the School of Medicine of the University of Barcelona, The Bellvitge Institute for Biomedical Research (IDIBELL) and an area of biotech development (Biopol).

Barcelona has recently made an enormous effort in biomedical research and the PEBC is the last new addition to this trend. The foundational goals of the PEBC are the development of high-quality basic research with a potential application for the benefit of the cancer patient in a scientific environment of international excellence.

I look forward to hearing from you, I extend my invitation to visit our place and our beautiful city, and I wish you a pleasant exploration of the PEBC web site.

My Best wishes,

Manel Esteller, M.D., Ph.D.
PEBC Director


© 2008® | PEBC | Todos los derechos reservados |  WEBMAIL  |  INTRANET  |  FTP